Medical Director, Maryland Proton Therapy Center
Education and Training
Aug 2002 – May 2006
MD, University of Pennsylvania School of Medicine
June 2006 – June 2007
Internship, Department of Medicine, Graduate Hospital, Philadelphia, PA
July 2007 – June 2011
Residency, Radiation Oncology Branch, National Capital Consortium (NCC), National Cancer Institute (NCI), National Institutes of Health (NIH)
July 2010 – June 2011
Chief Resident, Radiation Oncology, NCC, National Cancer Institute, NIH
Dr. Charles B. Simone, II is the Medical Director of the Maryland Proton Treatment Center and an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine. He is also the Chair of the Clinical Research Committee for the University of Maryland Greenebaum Comprehensive Cancer Center, as well as the Fellowship Director and the Director of the Stereotactic Radiation Therapy Program for the Department of Radiation Oncology. He is an internationally recognized expert in the use of proton therapy to treat thoracic malignancies and for reirradiation, and in the development of clinical trial strategies and innovative research in thoracic radiation oncology and stereotactic body radiation therapy.
He completed his undergraduate and medical school training at the University of Pennsylvania. He completed an internship in internal medicine, and then he completed residency training in radiation oncology at the National Cancer Institute, National Institutes of Health, where he served as chief resident. Prior to his appointment at University of Maryland, Dr. Simone was an Associate Professor of Radiation Oncology, Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Co-Director of the Penn Mesothelioma and Pleural Program for the University of Pennsylvania Health System, and Director of Clinical Research and Operations for the Department of Radiation Oncology at Penn.
Dr. Simone uses proton and photon radiation therapy to treat patients with lung cancer, malignant pleural mesothelioma, thymic malignancies, and other thoracic malignancies, as well as recurrent malignancies and sarcomas. He is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for thoracic malignancies. He has published >235 peer-reviewed scientific articles and book chapters and given >150 scientific lectures to national and international audiences.
He is the Chair of the Proton Collaborative Group (PCG) Executive Committee, Chair of the PCG Lung Committee, Chair of the American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee, and Chair of the American Society for Photobiology (ASP) Education Committee. He is appointed to the NRG Oncology Lung Cancer Core Committee; NRG Radiation Oncology Committee; NCI Thoracic Malignancies Steering Committee Mesothelioma Working Group; International Thymic Malignancy Interest Group (ITMIG) Research and Infrastructure Committee; ITMIG Thymic Carcinoma Workgroup; ASTRO Lung Cancer “Blue Ribbon” Panel; American College of Radiation Oncology (ACRO) Scientific Program Committee; American Radium Society (ARS) Scientific Program Committee; ASP Executive Council; PCG Reirradiation Committee; Particle Therapy Co-Operative Group (PTCOG) Scientific Committee; and multiple PTCOG Clinical Subcommittees. He is also the Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Journal of Clinical Oncology, Journal of Thoracic Disease, Frontiers in Oncology, and Translational Lung Cancer Research.
lung cancer, mesothelioma and thoracic malignancies